CLOVER HEALTH INVESTMENTS Business Summary

Clover Health Investments, Corp. (CLOV) is a technology-centric healthcare enterprise that generates revenue primarily through Medicare Advantage (MA) insurance premiums and the external licensing of its proprietary AI-driven clinical platform, Counterpart Health. The business is bifurcated into an Insurance segment, which manages high-retention PPO and HMO plans for approximately 153,000 members as of January 2026, and a non-insurance technology segment that utilizes a hybrid SaaS and shared-savings model to provide clinical decision support to third-party payers and providers. Following a 53% year-over-year membership surge and a strategic pivot toward its "Clover Assistant" software, the company is positioned to achieve its first full year of GAAP net income profitability in 2026. Clover competes against legacy managed care organizations like UnitedHealth Group, Humana, and CVS Health (Aetna), as well as specialized insurtechs such as Alignment Healthcare, distinguishing itself by maintaining a wide-network PPO model that leverages real-time data synthesis to reduce medical loss ratios (MLR) and improve clinical outcomes. The company was co-founded by Executive Chairperson Vivek Garipalli, a seasoned healthcare entrepreneur and founder of CarePoint Health, and CEO Andrew Toy, a former Google executive who previously founded the enterprise mobile security firm Divide. Toy’s expertise in systems architecture is the catalyst for Clover’s "physician-enablement" strategy, supported by a leadership team including CFO Peter Kuipers and Counterpart Health CEO Conrad Wai. The company’s board of directors includes high-profile figures such as Demetrios Kouzoukas, a former Director of the Center for Medicare at CMS, and Thomas L. Tran, the former CFO of Molina Healthcare who assumed the Audit Committee Chair in 2025 following the departure of Chelsea Clinton. Early institutional backing was led by Chamath Palihapitiya’s Social Capital via a 2021 SPAC merger, with additional investment from Sequoia Capital and GV (formerly Google Ventures), underscoring a pedigree rooted in both Silicon Valley technology and federal healthcare regulatory expertise.